Skip to main content
Erschienen in: Clinical Autonomic Research 3/2016

07.03.2016 | Review Article

Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension

verfasst von: Ahmed Elgebaly, Bassant Abdelazeim, Omar Mattar, Mohamed Gadelkarim, Rehab Salah, Ahmed Negida

Erschienen in: Clinical Autonomic Research | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Droxidopa has been approved for the treatment of neurogenic orthostatic hypotension (NOH) under the US Food and Drug Administration accelerated approval program, which warrants confirmatory evidence on long-term efficacy of droxidopa. Hereby, we synthesize evidence from published randomized controlled trials (RCTs) about the safety and efficacy of droxidopa for patients with neurogenic orthostatic hypotension.

Methods

A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager version 5.3 for Windows. Subgroup analysis and sensitivity analysis were conducted to investigate long-term durability of droxidopa against placebo.

Results

Four RCTs with a total of 485 patients (droxidopa, n = 246; placebo, n = 239) were eligible for the final analysis. The mean difference (MD) of change in the main outcomes from baseline to endpoint favored droxidopa than placebo [Orthostatic Hypotension Questionnaire (OHQ) MD −0.61, P = 0.004; dizziness/lightheadedness score MD −0.83, P = 0.008; and standing systolic blood pressure (SBP) MD 4.09, P = 0.03]. The efficacy of droxidopa decreased gradually after 2 weeks, and its statistical significance was lost after 8 weeks (OHQ score MD −0.18, P = 0.61; dizziness/lightheadedness score MD −0.71, P = 0.11; and standing SBP MD 2.96, P = 0.29). None of the adverse events were significantly higher in the case of droxidopa compared to placebo.

Conclusion

Droxidopa is a safe and effective drug for the short-term management of NOH symptoms. However, current evidence is insufficient to confirm the efficacy of droxidopa for long-term use. Therefore, further studies with increased sample size are needed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kaufmann H (1996) Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res 6:125–126CrossRefPubMed Kaufmann H (1996) Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res 6:125–126CrossRefPubMed
2.
Zurück zum Zitat Freeman R, Wieling W, Axelrod FB et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21:69–72CrossRefPubMed Freeman R, Wieling W, Axelrod FB et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21:69–72CrossRefPubMed
4.
Zurück zum Zitat Isaacson SH, Skettini J (2014) Neurogenic orthostatic hypotension in Parkinson’s disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag 10:169CrossRefPubMedPubMedCentral Isaacson SH, Skettini J (2014) Neurogenic orthostatic hypotension in Parkinson’s disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag 10:169CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Horowitz DR, Kaufmann H (2001) Autoregulatory cerebral vasodilation occurs during orthostatic hypotension in patients with primary autonomic failure. Clin Auton Res 11:363–367. doi:10.1007/BF02292768 CrossRefPubMed Horowitz DR, Kaufmann H (2001) Autoregulatory cerebral vasodilation occurs during orthostatic hypotension in patients with primary autonomic failure. Clin Auton Res 11:363–367. doi:10.​1007/​BF02292768 CrossRefPubMed
6.
Zurück zum Zitat Maule S, Papotti G, Naso D et al (2007) Orthostatic hypotension: evaluation and treatment. Cardiovasc Hematol Disord Drug Targets 7:63–70CrossRefPubMed Maule S, Papotti G, Naso D et al (2007) Orthostatic hypotension: evaluation and treatment. Cardiovasc Hematol Disord Drug Targets 7:63–70CrossRefPubMed
11.
Zurück zum Zitat Mathias CJ, Kimber JR (1999) Postural hypotension: causes, clinical features, investigation, and management. Annu Rev Med 50:317–336CrossRefPubMed Mathias CJ, Kimber JR (1999) Postural hypotension: causes, clinical features, investigation, and management. Annu Rev Med 50:317–336CrossRefPubMed
12.
Zurück zum Zitat Kaufmann H, Brannan T, Krakoff L et al (1988) Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology 38:951–956CrossRefPubMed Kaufmann H, Brannan T, Krakoff L et al (1988) Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology 38:951–956CrossRefPubMed
15.
18.
Zurück zum Zitat Freeman R, Landsberg L, Young J (1999) The treatment of neurogenic orthostatic hypotension with 3,4-dl-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology 53:2151–2157. doi:10.1212/WNL.53.9.2151 CrossRefPubMed Freeman R, Landsberg L, Young J (1999) The treatment of neurogenic orthostatic hypotension with 3,4-dl-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology 53:2151–2157. doi:10.​1212/​WNL.​53.​9.​2151 CrossRefPubMed
19.
Zurück zum Zitat Mathias CJ, Senard JM, Braune S et al (2001) L-threo-dihydroxyphenylserine (l-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 11:235–242. doi:10.1007/BF02298955 CrossRefPubMed Mathias CJ, Senard JM, Braune S et al (2001) L-threo-dihydroxyphenylserine (l-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 11:235–242. doi:10.​1007/​BF02298955 CrossRefPubMed
22.
Zurück zum Zitat Hauser RA, Isaacson S, Lisk JP et al (2014) Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B). Neurology 00:1–9. doi:10.1002/mds.26086 Hauser RA, Isaacson S, Lisk JP et al (2014) Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B). Neurology 00:1–9. doi:10.​1002/​mds.​26086
24.
Zurück zum Zitat Hauser RA, Hewitt LA, Isaacson S (2014) Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson’s disease (NOH306A). J Parkinsons Dis 4:57–65. doi:10.3233/JPD-130259 PubMed Hauser RA, Hewitt LA, Isaacson S (2014) Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson’s disease (NOH306A). J Parkinsons Dis 4:57–65. doi:10.​3233/​JPD-130259 PubMed
Metadaten
Titel
Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension
verfasst von
Ahmed Elgebaly
Bassant Abdelazeim
Omar Mattar
Mohamed Gadelkarim
Rehab Salah
Ahmed Negida
Publikationsdatum
07.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Autonomic Research / Ausgabe 3/2016
Print ISSN: 0959-9851
Elektronische ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-016-0349-7

Weitere Artikel der Ausgabe 3/2016

Clinical Autonomic Research 3/2016 Zur Ausgabe